<DOC>
	<DOCNO>NCT00051675</DOCNO>
	<brief_summary>The purpose study evaluate safety , immunogenicity , tolerability monoclonal antibody administer subcutaneously treatment advance cancer ovary , breast , lung , prostate , colon rectum either refractory standard therapy therapy may potentially major benefit exist .</brief_summary>
	<brief_title>Phase I Study Monoclonal Antibody Treatment Advanced Adenocarcinomas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject adenocarcinoma ovary , breast , lung , prostate , colon rectum . 2 . Subject advanced metastatic adenocarcinoma either refractory standard therapy therapy may potentially major benefit exist . 3 . Subject measurable lesion . Subjects prostate cancer nonmeasurable lesion . 4 . Subject may prior radiation therapy complete least four week prior study entry , subject recover acute toxicity therapy , measurable lesion nonirradiated area . 5 . Subject may prior chemotherapy , cytokine therapy immunotherapy complete least four week prior study entry subject recover acute toxicity therapy . 6 . Subjects tumor responsive hormone therapy may prior hormonal therapy complete least four week prior study entry . Hormonal therapy prostate cancer may continue must change less four week prior study entry . 7 . Subject performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) scale . 8 . Subject estimate life expectancy least 12 week . 9 . Subject least 18 year age . 10 . Subject adequate organ function define follow : Hematologic : Platelets 100 × 109/L Hemoglobin 9.0 g/dL Total WBC count 3.5 × 109/L PT/INR PTT within institutional limit subject receive therapeutic anticoagulation low dose anticoagulant maintain venous catheter patency ( subject anticoagulant therapy allow ) . Hepatic : Bilirubin 2.0 mg/dL Aspartate transaminase ( AST ) alanine transaminase ( ALT ) 3 time upper limit normal ( AST ALT 5 time upper limit normal acceptable liver tumor involvement elevation due tumor involvement ) Renal : Serum creatinine 1.5 mg/dL Pancreatic : Amylase lipase upper limit normal ( ULN ) 11 . Signed informed consent form . 12 . Male female subject reproductive potential must use approved contraceptive method . 13 . Female subject reproductive potential must negative serum pregnancy test within seven day study enrollment . Exclusion Criteria 1 . Subject serious concomitant systemic disorder incompatible study . 2 . Subject use investigational agent within 30 day study entry . 3 . Subject pregnant lactating . 4 . Subject undergone bone marrow transplant . 5 . Subject know HIV+ recognize immunodeficiency disease . ( Note : As mechanism action ING1 ( heMAb ) ADCC , subject need immunocompetent ) . 6 . Subject history severe allergic anaphylactic reaction monoclonal antibody antibody fragment . ( Note : For subject receive prior ING1 ( heMAb ) , HAHA titer negative . ) 7 . Subject concurrent prior malignancy , except adequatelytreated basal cell squamous cell skin cancer , adequatelytreated noninvasive carcinoma cancer subject diseasefree least two year . 8 . Subject active autoimmune disease require chronic treatment . 9 . Subject use use immunosuppressive drug cyclosporine , ACTH corticosteroid within four week prior enrollment . 10 . Subject brain metastasis know history brain metastasis . 11 . Subject history alcoholism chronic pancreatitis family history acute chronic pancreatitis . 12 . Subject hypertriglyceridemia ( Serum triglycerides 500 mg/dL ) . 13 . Subject history gall bladder disease gallstone ( postcholecystectomy subject allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>